Cosmo Pharmaceuticals SA, a closely held developer of gastrointestinal products, has spun out around half of its subsidiary, Cassiopea SpA, on the SIX Swiss Stock Exchange, but the majority shareholders of Cosmo will remain majority shareholders of Cassiopea.
A public US share offering of Pieris Pharmaceuticals Inc (formerly Pieris AG) has been priced at $2.75 per share for the 9,090,909 shares on offer, giving net proceeds of $22.7 million, a figure that could rise if over-allotments are exercised.
Munich-based Medigene AG has secured €46.4 million in new capital through the placement of shares with existing shareholders and new institutional investors to support clinical development of its dendritic cell (DC) vaccines against cancer and other immunotherapy projects.
Celgene Corporation is set to pay $1 billion for access to engineered T cell technologies developed by Juno Therapeutics Inc in one of the year’s most significant oncology deals. The 10-year collaboration will focus on chimeric antigen receptor technology and T cell receptor technologies.
Novartis is increasing its involvement in neurology with the acquisition of Spinifex Pharmaceuticals Inc, a privately held Australian-American company that is developing a potentially novel treatment for chronic pain and particularly neuropathic pain.
Kiadis Pharma NV said that its previously announced initial public offering on the Amsterdam and Brussels Euronext exchanges will consist of 2,272,727 shares to be priced at between €11 and €13.75 per share with a final price to be announced on 1 July..
Cosmo Pharmaceuticals SA, a specialty developer of gastro-intestinal products and a generic drug manufacturer, has announced plans to float a subsidiary on the Swiss Stock Exchange where it has a listing of its own. Terms of the offering are to be disclosed later.
Targovax AS of Norway and Oncos Therapeutics Oy of Finland have agreed to an all-share merger to create a Nordic oncology company with a combined portfolio of early-stage cancer vaccines poised to take advantage of new opportunities in immuno-oncology.
Swedish Orphan Biovitrum AB (Sobi), a developer of drugs for rare diseases, has terminated discussions with an undisclosed party in relation to a possible takeover proposal for the company. Sobi announced the end of discussions on 8 June.
Allergy Therapeutics Plc, a UK-based specialty pharmaceutical company, has paid €3.8 million in cash for Alerpharma SA of Spain in order to increase its presence on the Spanish market for allergy therapies where it already has a subsidiary.